Concert Pharmaceuticals, Inc.
https://www.concertpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Concert Pharmaceuticals, Inc.
Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib
Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.
Soterios Topical Could Take On JAK Class In Alopecia Areata
The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
India Pharma Action: GMP Enforcement, CDMO Rage And Private Equity Interest
In this second instalment on key trends playing out in India, Scrip talks to industry leaders on the marked shift in GMP norms that could potentially resize Indian manufacturing, large player interest in the CDMO space and M&A activity, where PE firms may be the “most aggressive” buyers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- ADMET
-
Molecular Diversity
- Natural Products
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Concert Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice